Cargando…

CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment

Adult T‐cell leukemia/lymphoma (ATL) patients have a very poor prognosis. The humanized anti‐CCR4 therapeutic monoclonal antibody, mogamulizumab, is a key agent for ATL treatment. Our previous integrated molecular analysis demonstrated that among all the driver genes in ATL, CCR7 gene alterations we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakamoto, Yuma, Ishida, Takashi, Masaki, Ayako, Murase, Takayuki, Ohtsuka, Eiichi, Takeshita, Morishige, Muto, Reiji, Iwasaki, Hiromi, Ito, Asahi, Kusumoto, Shigeru, Nakano, Nobuaki, Tokunaga, Masahito, Yonekura, Kentaro, Tashiro, Yukie, Iida, Shinsuke, Utsunomiya, Atae, Ueda, Ryuzo, Inagaki, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087024/ https://www.ncbi.nlm.nih.gov/pubmed/36043457 http://dx.doi.org/10.1002/hon.3072

Ejemplares similares

Immunohistochemistry for CCR4 C‐terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T‐cell leukemia/lymphoma
por: Fujii, Keiichiro, et al.
Publicado: (2020)

Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

Clinical significance of CD28 gene‐related activating alterations in adult T‐cell leukaemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2020)

Clinicopathological significance of CD28 overexpression in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

Cutaneous adverse reactions and anti-tumor effects of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma
por: Yonekura, Kentro, et al.
Publicado: (2015)

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
por: Tanaka, Norio, et al.
Publicado: (2022)

Clinical significance of the immunoglobulin G heavy‐chain repertoire in peripheral blood mononuclear cells of adult T‐cell leukaemia–lymphoma patients receiving mogamulizumab
por: Nosaka, Kisato, et al.
Publicado: (2021)

Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma
por: Utsunomiya, Atae
Publicado: (2014)

Effect of a novel anti-CCR4 monoclonal antibody (Mogamulizmab) on skin lesions of adult T-cell leukemia-lymphoma (ATL) and its adverse skin reactions (ASR)
por: Yonekura, Kentaro, et al.
Publicado: (2014)

Landscape of immunoglobulin heavy chain γ gene class switch recombination in patients with adult T-cell leukemia–lymphoma
por: Hiramatsu, Hiroaki, et al.
Publicado: (2022)

Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies
por: Ishida, Takashi, et al.
Publicado: (2017)

Depletion of central memory CD8(+) T cells might impede the antitumor therapeutic effect of Mogamulizumab
por: Maeda, Yuka, et al.
Publicado: (2021)

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
por: Musiek, Amy C. M., et al.
Publicado: (2021)

Clinical landscape of TP73 structural variants in ATL patients
por: Hiramatsu, Hiroaki, et al.
Publicado: (2023)

Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas
por: Kitadate, Akihiro, et al.
Publicado: (2018)

Promising results of an anti-CCR4 antibody, KW-0761, for relapsed Adult T-Cell Leukemia-Lymphoma (ATL)
por: Utsunomiya, Atae, et al.
Publicado: (2011)

Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study
por: Ishida, Takashi, et al.
Publicado: (2015)

Chronic type adult T-cell leukemia-lymphoma after autolougous stem cell transplantation for ALK-negative anaplastic large cell lymphoma
por: Utsunomiya, Atae, et al.
Publicado: (2015)

Safety and effectiveness of mogamulizumab in relapsed or refractory adult T‐cell leukemia‐lymphoma
por: Ishitsuka, Kenji, et al.
Publicado: (2019)

Presence of cutaneous lesion is a poor prognostic factor in patients with smoldering-type adult T-cell leukemia-lymphoma
por: Yonekura, Kentaro, et al.
Publicado: (2011)

Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals
por: Masaki, Ayako, et al.
Publicado: (2018)

Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF
por: Yano, Hiroki, et al.
Publicado: (2008)

Alopecia areata after mogamulizumab treatment
por: Raval, Neel S., et al.
Publicado: (2021)

Serum prohepcidin levels are potential prognostic markers in patients with multiple myeloma
por: HARAGUCHI, KOUICHI, et al.
Publicado: (2012)

Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors
por: Saito, Takuro, et al.
Publicado: (2021)

Humanized anti CCR4 antibody KW0761 targets HTLV-1 infected CD4+ CCR4+ and CD8+CCR4+ T cells to treat HAM/TSP
por: Yamano, Yoshihisa, et al.
Publicado: (2015)

Alopecia areata-like presentations with mogamulizumab therapy
por: Kincaid, Colin M., et al.
Publicado: (2023)

Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL)
por: Phillips, Adrienne, et al.
Publicado: (2015)

Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors
por: Fujikawa, Kaoru, et al.
Publicado: (2023)

Marketing approval of mogamulizumab: A triumph for glyco-engineering
por: Beck, Alain, et al.
Publicado: (2012)

Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report
por: FUJITA, YUKIE, et al.
Publicado: (2016)

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma
por: Ollila, Thomas A, et al.
Publicado: (2019)

Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma
por: Kwan, Jennifer M., et al.
Publicado: (2021)

Clinical significance of tryptophan catabolism in Hodgkin lymphoma
por: Masaki, Ayako, et al.
Publicado: (2017)

Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma
por: Kinoshita, Shiori, et al.
Publicado: (2018)

Successful treatment strategy in corporating mogamulizumab and cord blood transplantation in aggressive adult T-cell leukemia-lymphoma: a case report
por: Nakata, Keiichi, et al.
Publicado: (2020)

Long‐term disease control and safety with the anti‐CCR4 antibody mogamulizumab: Post‐hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T‐cell lymphoma
por: Bagot, Martine, et al.
Publicado: (2022)

Mogamulizumab Treatment in a Hemodialysis Patient with Adult T-Cell Leukemia/Lymphoma
por: Yoshihara, Mari, et al.
Publicado: (2014)

Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy
por: Fujimura, Taku, et al.
Publicado: (2018)

Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma
por: Watson, Sutton, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jseollr4bmobjt0odnpip6j29g